Iantrek, a medical technology company focused on bio-interventional ophthalmic surgery, has secured $30 million in growth capital from Trinity Capital, a Phoenix-based alternative asset manager listed on Nasdaq. The debt facility will support commercial expansion, pipeline development, manufacturing scale-up, and market access initiatives to broaden physician and patient adoption.
Iantrek develops minimally invasive surgical technologies designed to treat chronic eye diseases, particularly glaucoma, by restoring the eye’s natural fluid outflow pathways rather than bypassing or removing tissue. Its lead commercial product, AlloFlo Uveo, launched in October 2025. The company is also introducing AlloSpan Canal in the U.S., which will make Iantrek the only organization offering complementary surgical solutions targeting both natural outflow pathways for a more comprehensive approach to glaucoma intervention. The Trinity financing follows a Series C raise in 2025 that included lead equity investors USVP, Sectoral, aMoon, and Visionary Ventures.
Trinity Capital has deployed more than $5.5 billion across over 463 investments since its founding in 2008, with lending verticals spanning Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences.
KEY QUOTES:
“We believe Iantrek’s innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology. We are pleased to support their team as they enter this next phase of rapid growth.”
Rob Lake, Senior Managing Director of Life Sciences, Trinity Capital
“This financing is a strategic step to keep pace with growing physician demand for our platform. It positions us to accelerate adoption of AlloFlo Uveo, our lead commercial technology, and advance the next wave of bio-interventional innovation.”
Adam Szaronos, Chief Executive Officer, Iantrek
